Darren J. Walsh

Mr. Darren J. Walsh

University Hospital Waterford, Waterford, Ireland
+1
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2024 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
CEColm Mac Eochagain
Colm Mac Eochagain
RPRobert Power
Robert Power
CSChristine Sam
Christine Sam
NGNicolas M Gonzalez-Senac
Nicolas M Gonzalez-Senac
DWDarren J. Walsh
Darren J. Walsh
Nicolò Matteo Luca BattistiNicolò Matteo Luca Battisti
Nicolò Matteo Luca Battisti
Immune checkpoint inhibitors (ICI) have transformed the management of cancer, particularly for older adults, who constitute a majority of the global cancer patient population. This study aimed to assess the inclusion, characteristics, and reporting of older adults enrolled in Food and Drug Administration (FDA) registration clinical trials of ICI between 2018 and 2022. Clinical trials of ICI leading to an FDA approval in solid tumor oncology between 2018 and 2022 were included. Primary study reports and all available secondary publications were assessed. The availability and completeness of older subgroup data for protocol-defined clinical efficacy endpoints, health-related quality of life (HRQOL) and toxicity outcomes, and baseline characteristics were assessed according to predefined criteria which categorized reporting completeness hierarchically in relation to the availability of published data, including effect size, sample size, and measures of precision. 53 registration trials were included, involving a total of 37,094 participants. Most trials (64.2%) were of ICI combination therapy. 42.3% of patients were aged≥65 years; 11.1% were aged≥75. No trials specified an upper age limit for eligibility. 98.1% of trials excluded patients with European Cooperative Oncology Group performance status>1. 87.2% of primary efficacy endpoints and 17.9% of secondary efficacy endpoints were reported completely for older adults. Five studies (9.4%) reported baseline characteristics, three (6.1%) reported HRQOL assessments, and four (7.5%) reported toxicity outcomes completely among older subgroups. No trials conducted baseline geriatric assessments or reported geriatric-specific symptoms or quality of life scales. This analysis highlights significant deficits in the enrollment and reporting of older subgroups in pivotal trials of ICI therapy. The findings highlight an urgent need for improved reporting and inclusion standards in clinical trials of ICI to better inform treatment decisions for older adults.

26 August 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
MHMunzir Hamid
Munzir Hamid
MHMichelle Hannan
Michelle Hannan
NONay Myo Oo
Nay Myo Oo
PLPaula Lynch
Paula Lynch
DWDarren J. Walsh
Darren J. Walsh
AHAnne M. Horgan
Anne M. Horgan
The Comprehensive Geriatric Assessment (CGA) is recommended to guide treatment choices in older patients with cancer. Patients ≥ 70 years referred to our oncology service with a new cancer diagnosis are screened using the G-8. Patients with a score of ≤14 are eligible to attend the Geriatric Oncology and Liaison (GOAL) Clinic in our institution, with referral based on physician discretion. Referred patients undergo multidimensional assessments at baseline. CGA domains assessed include mobility, nutritional, cognitive, and psychological status. Chemotherapy toxicity risk is estimated using the Cancer Aging and Research Group (CARG) calculator. We undertook a retrospective analysis of patients attending the GOAL clinic over a 30-month period to April 2021. The objective was to determine rates of treatment dose modifications, delays, discontinuation, and unscheduled hospitalizations as surrogates for cytotoxic therapy toxicity in these patients. These data were collected retrospectively. Ninety-four patients received chemotherapy; the median age was 76 (70–87) and 45 were female (48%). Seventy-five (80%) had an ECOG PS of 0–1. Seventy-two (77%) had gastrointestinal cancer, and most had stage III (47%) or IV (40%) disease. Chemotherapy with curative intent was received by 51% (n = 48) and 51% received monotherapy. From the CGA, the median Timed Up and Go was 11 s (7.79–31.6), and 90% reported no falls in the prior 6 months. The median BMI was 26.93 (15.43–39.25), with 70% at risk or frankly malnourished by the Mini Nutritional Assessment. Twenty-seven (29%) patients had impaired cognitive function. Forty-three (46%) had a high risk of toxicity based on the baseline CARG toxicity calculator. Twenty-six (28%) required dose reduction, 55% (n = 52) required a dose delay, and 36% (n = 34) had a hospitalization due to toxicity. Thirty-nine patients (42%) discontinued treatment due to toxicity. Despite intensive assessment, clinical optimization and personalized treatment decisions, older adults with cancer remain at high risk of chemotherapy toxicity.

19 May 2023 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
DWDarren J. Walsh
Darren J. Walsh
KKKavita Kantilal
Kavita Kantilal
CHChloé Herledan
Chloé Herledan
GNGinah Nightingale
Ginah Nightingale
VSVanya Slavova-Boneva
Vanya Slavova-Boneva
KKKumud Kantilal
Kumud Kantilal

30 March 2024 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
DWDarren J. Walsh
Darren J. Walsh
MOMichelle O'Driscoll
Michelle O'Driscoll
Laura SahmLaura Sahm
Laura Sahm
AMAnne Marie Meagher
Anne Marie Meagher
PDPedro Doblas
Pedro Doblas
AHAnne M. Horgan
Anne M. Horgan

7 June 2023 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
DWDarren J. Walsh
Darren J. Walsh
Laura SahmLaura Sahm
Laura Sahm
MOMichelle O'DRiscoll
Michelle O'DRiscoll
BBBronagh Bolger
Bronagh Bolger
HAHitam Ameen
Hitam Ameen
AHAnne M. Horgan
Anne M. Horgan

18 June 2023 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
DWDarren J. Walsh
Darren J. Walsh
Laura SahmLaura Sahm
Laura Sahm
MOMichelle O’dRiscoll
Michelle O’dRiscoll
ETEoin Tabb
Eoin Tabb
MHMichelle Hannan
Michelle Hannan
AHAnne M Horgan
Anne M Horgan
Introduction: Medication reconciliation as part of a Comprehensive Geriatric Assessment by a specialist pharmacist is a process that has been shown to be beneficial in terms of medication adherence in patients taking oral anticancer medication and potentially cost-effective in cancer patients. Medication review guidelines in older adults with cancer suggest using polypharmacy (≥ 5 medications) as an indication for medication review in older adults with cancer. Case report: We present a case where a medication review as part of a Comprehensive Geriatric Assessment in the absence of polypharmacy resulted in two pharmacist interventions when standard care resulted in no intervention. A 71-year-old male prescribed capecitabine for rectal cancer had a medication reconciliation done as standard care before starting an oral anticancer medication. He then proceeded to get a medication review as part of a Comprehensive Geriatric Assessment and was deemed to have a potentially excessive anticholinergic burden and underprescribed gastro protection. This case is interesting as it occurred in a patient who would not have met the current inclusion criteria for a medication review as part of a Comprehensive Geriatric Assessment. Management and outcome: As a result of the Comprehensive Geriatric Assessment, a letter was written to the patient's general practitioner, recommending a change to anti-depressant therapy to optimise anticholinergic burden, as well as introducing a proton-pump inhibitor upon completion of the Capecitabine protocol concurrent with radiotherapy, to confer gastro-protection against the antidepressant medication, as per the START criteria. Upon discharge from medical oncology, neither of the changes had been adopted by the patient's general practitioner. This highlights one of the challenges facing clinical pharmacists in an outpatient setting, where evidence-based recommendations are not always implemented as care transitions from tertiary to primary care. Conclusion: Comprehensive Geriatric Assessment is a process that identifies potential issues in older adults with cancer that aren’t identified with standard medication review. This is also evident for medication reviews as part of a Comprehensive Geriatric Assessment, and where resources allow, and recommendations are likely to be accepted, it should be offered to all older adults with cancer. Pharmacists are still faced with challenges in implementing recommendations from medication reviews, particularly in healthcare systems where pharmacist prescribing has yet to be introduced.